Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’ - Peter Almond finished a trial for Donanemab in September having been on the drug for three years ...

A new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10–13 months in the early stage of Alzheimer's disease.

Donanemab is a monoclonal antibody given as an infusion. The medication binds to proteins that build up as amyloid plaques in the brain. By binding to the plaque proteins, the drug's antibodies ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with early-stage disease.

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

During the clinical trial for donanemab, 2.9% of those on the drug had a serious side effect related to ARIA-E, and three patients died, according to the Alzheimer’s Society.

Marketing approval had been sought based on data from the TRAILBLAZER-ALZ 2 clinical trial, which compared donanemab with placebo in 1736 patients with early symptomatic AD (prodromal AD and mild ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early symptomatic Alzheimer's disease, a secondary analysis of trial data showed ...

Donanemab works similarly to lecanemab, another promising Alzheimer's drug. Patients on lecanemab need infusions every two weeks, while donanemab is administered once a month.

Solano Garcia credits the drug donanemab, which she began taking as part of a clinical trial at the University of Southern California. The Food and Drug Administration approved the drug, now ...

The UK's Medicines and Healthcare products Regulatory Agency approved donanemab, branded as Kisunla, making it the second treatment for Alzheimer's in the country after Leqembi, which has been ...